CN112739314A - 用于治疗癌症和自体免疫疾病的组合物和方法 - Google Patents

用于治疗癌症和自体免疫疾病的组合物和方法 Download PDF

Info

Publication number
CN112739314A
CN112739314A CN201980062092.7A CN201980062092A CN112739314A CN 112739314 A CN112739314 A CN 112739314A CN 201980062092 A CN201980062092 A CN 201980062092A CN 112739314 A CN112739314 A CN 112739314A
Authority
CN
China
Prior art keywords
optionally substituted
hydrogen
substituted substituent
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062092.7A
Other languages
English (en)
Chinese (zh)
Inventor
拉马钱德兰·穆拉利
兰达尔·麦克纳利
潘欣磊
俞政孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to CN202410436075.8A priority Critical patent/CN118662499A/zh
Publication of CN112739314A publication Critical patent/CN112739314A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CN201980062092.7A 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法 Pending CN112739314A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410436075.8A CN118662499A (zh) 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716101P 2018-08-08 2018-08-08
US62/716,101 2018-08-08
PCT/US2019/045742 WO2020033715A1 (en) 2018-08-08 2019-08-08 Compositions and methods for treating cancer and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410436075.8A Division CN118662499A (zh) 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法

Publications (1)

Publication Number Publication Date
CN112739314A true CN112739314A (zh) 2021-04-30

Family

ID=69415674

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980062092.7A Pending CN112739314A (zh) 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法
CN202410436075.8A Pending CN118662499A (zh) 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410436075.8A Pending CN118662499A (zh) 2018-08-08 2019-08-08 用于治疗癌症和自体免疫疾病的组合物和方法

Country Status (7)

Country Link
US (1) US20210299176A1 (https=)
EP (1) EP3833323A4 (https=)
JP (2) JP7530346B2 (https=)
KR (2) KR102753455B1 (https=)
CN (2) CN112739314A (https=)
CA (1) CA3108796A1 (https=)
WO (1) WO2020033715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
CN113429488B (zh) * 2021-07-14 2022-08-30 海正生物制药有限公司 GITR/TGF-β双靶向融合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809589A (zh) * 2003-05-23 2006-07-26 Wyeth公司 Gitr配体和gitr配体相关分子和抗体及其应用
US20100297046A1 (en) * 2006-03-31 2010-11-25 Dynamis Therapeutics, Inc. Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
CN107208138A (zh) * 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 用于癌症预后和治疗的方法和组合物
CN108064242A (zh) * 2014-05-28 2018-05-22 阿吉纳斯公司 抗gitr抗体和其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
PL3242947T3 (pl) 2015-01-09 2021-01-11 Oncosec Medical Incorporated Terapia genowa i elektroporacja do leczenia zmian złośliwych

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809589A (zh) * 2003-05-23 2006-07-26 Wyeth公司 Gitr配体和gitr配体相关分子和抗体及其应用
US20100297046A1 (en) * 2006-03-31 2010-11-25 Dynamis Therapeutics, Inc. Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
CN108064242A (zh) * 2014-05-28 2018-05-22 阿吉纳斯公司 抗gitr抗体和其使用方法
CN107208138A (zh) * 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 用于癌症预后和治疗的方法和组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMAL EPHREM等: "Modulation of Treg cells/T effector function by GITR signaling is context–dependent", 《EUR. J. IMMUNOL.》 *
AMAL EPHREM等: "Modulation of Treg cells/T effector function by GITR signaling is context–dependent", 《EUR. J. IMMUNOL.》, no. 42, 31 December 2013 (2013-12-31), pages 2421 - 2429 *
MARY JO TURK等: "Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells", 《J. EXP. MED.》 *
MARY JO TURK等: "Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells", 《J. EXP. MED.》, vol. 200, no. 6, 20 September 2004 (2004-09-20), pages 771 - 782, XP009148395, DOI: 10.1084/jem.20041130 *

Also Published As

Publication number Publication date
JP2024156758A (ja) 2024-11-06
KR102753455B1 (ko) 2025-01-10
KR20250025409A (ko) 2025-02-21
KR20210041036A (ko) 2021-04-14
WO2020033715A1 (en) 2020-02-13
EP3833323A1 (en) 2021-06-16
EP3833323A4 (en) 2022-08-10
JP7530346B2 (ja) 2024-08-07
US20210299176A1 (en) 2021-09-30
CA3108796A1 (en) 2020-02-13
JP2021534110A (ja) 2021-12-09
CN118662499A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
JP7587528B2 (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
CN111148527B (zh) 通用abt化合物及其用途
AU2021203492A1 (en) Nucleic acid vaccines
US20250090560A1 (en) T cell receptors for immunotherapy
JP2024156758A (ja) 癌及び自己免疫疾患を治療するための組成物及び方法
US20220073578A1 (en) Methods of treating aging-related disorders
JP2001522239A (ja) ８７個のヒト分泌タンパク質
KR20180118105A (ko) 면역치료를 위한 slc45a2 펩티드
KR20230031280A (ko) 노화 관련 장애의 치료 방법
CA3104674A1 (en) Natural killer cells
US20250121026A1 (en) Compositions and methods for treating fibrosis
US20240024438A1 (en) Methods and compositions comprising mhc class peptides
US20220370586A1 (en) Method of generating activated t cells for cancer therapy
JP3924330B2 (ja) 新規タンパク質、その遺伝子、アポトーシス誘導用試薬及び抗ガン剤
KR20230172572A (ko) Mhc 부류 i 펩타이드를 포함하는 방법 및 조성물
ITUB20159749A1 (it) Molecole di acidi nucleici codificanti proteine chimeriche cspg4 e relativi usi terapeutici

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210430

RJ01 Rejection of invention patent application after publication